Never Give Up: Amarin Will Appeal Latest Vascepa Patent Loss
Company Still Sees Profit Potential Even With US Generic Competitors
A Federal Circuit panel affirmed a district court decision in favor of two generics makers, but Amarin will seek a hearing from the full 12-member appellate court. Vascepa marketing is unchanged for now.
